DUBLIN–(BUSINESS WIRE)–The “Alzeimer’s Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025” report has been added to ResearchAndMarkets.com’s offering.
The global alzeimer’s drugs market grew at a CAGR of around 8% during 2014-2019. Looking forward, the global alzeimer’s drugs market to continue its moderate growth during the next five years.
Alzheimer’s is a disease characterized by the degeneration of nerve cells in several areas of the brain. It causes loss of cognitive function, such as memory, language, thinking and behavior. The common symptoms of Alzheimer’s include depression, memory impairment, loss of inhibitions, and problems with thinking and reasoning.
It is usually diagnosed by performing physical exams, blood tests, brain imaging, and mental status and neuro-psychological testing. According to the results, doctors prescribe different medications to alleviate symptoms. Alzheimer’s drugs influence the functions of neurotransmitters, the chemicals involved in carrying messages between nerve cells in the brain.
Diabetes, obesity, heart diseases and high blood pressure (BP), in confluence with sedentary lifestyles, unhealthy dietary patterns and smoking, are some of the factors known to increase the chances of developing Alzheimer’s disease. An increase in the prevalence of these ailments and lifestyle choices among the masses, coupled with the rising geriatric population, represents one of the key factors driving the market growth.
Furthermore, the leading pharmaceutical companies are focusing on the development of drugs that prevent the disease and provide long-lasting improvements in cognitive functions. The market growth is further supported by the expansion of telehealth services and the growing traction of online pharmacies. These platforms have enabled disease diagnosis and drug delivery in remote regions. (Read more…)
Apart from this, various Alzheimer’s drugs are presently under late-stage clinical trials, including Aducanumab, Solanezumab and Insulin. The development of these drugs is anticipated to propel the market growth in the coming years.
Key Questions Answered in This Report:
- How has the global alzeimer’s drugs market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global alzeimer’s drugs market?
- What are the key regional markets?
- What is the breakup of the market based on the drug class?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global alzeimer’s drugs market and who are the key players?
- What is the degree of competition in the industry
Key Topics Covered:
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.4 Market Estimation
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Alzeimer’s Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Class
6.1 Donepezil
6.2 Galantamine
6.3 Rivastigmine
6.4 Memantine
6.5 Others
7 Market Breakup by Distribution Channel
7.1 Hospital Pharmacy
7.2 Retail Pharmacy
7.3 Online Stores
7.4 Others
8 Market Breakup by Region
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
- Abbvie Inc.
- AstraZeneca PLC
- Biogen Inc.
- Daiichi Sankyo Company Limited
- Eisai Co. Ltd.
- Eli Lilly
- Company
- H. Lundbeck A/S
- F. Hoffmann-La Roche AG
- Merck & Co. Inc.
- Novartis AG
- Ono Pharmaceutical Co. Ltd.
- Pfizer Inc
- Teva Pharmaceutical Industries Limited
For more information about this report visit https://www.researchandmarkets.com/r/4af9aa
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900